- Home
- LB vs VRDN Comparison
LB vs VRDN Comparison
Compare LB & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LB
- VRDN
- Stock Information
- Founded
- LB 1992
- VRDN 2006
- Country
- LB United States
- VRDN United States
- Employees
- LB N/A
- VRDN N/A
- Industry
- LB
- VRDN Medical Specialities
- Sector
- LB
- VRDN Health Care
- Exchange
- LB NYSE
- VRDN Nasdaq
- Market Cap
- LB 1.6B
- VRDN 1.3B
- IPO Year
- LB 2024
- VRDN N/A
- Fundamental
- Price
- LB $56.70
- VRDN $16.38
- Analyst Decision
- LB Buy
- VRDN Strong Buy
- Analyst Count
- LB 9
- VRDN 11
- Target Price
- LB $62.13
- VRDN $38.50
- AVG Volume (30 Days)
- LB 469.1K
- VRDN 754.2K
- Earning Date
- LB 08-06-2025
- VRDN 08-07-2025
- Dividend Yield
- LB 0.70%
- VRDN N/A
- EPS Growth
- LB N/A
- VRDN N/A
- EPS
- LB 0.02
- VRDN N/A
- Revenue
- LB $134,891,000.00
- VRDN $302,000.00
- Revenue This Year
- LB $85.89
- VRDN N/A
- Revenue Next Year
- LB $16.76
- VRDN $17,102.33
- P/E Ratio
- LB $3,330.46
- VRDN N/A
- Revenue Growth
- LB 77.50
- VRDN 4.86
- 52 Week Low
- LB $26.51
- VRDN $9.90
- 52 Week High
- LB $87.60
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- LB N/A
- VRDN 67.06
- Support Level
- LB N/A
- VRDN $13.84
- Resistance Level
- LB N/A
- VRDN $17.48
- Average True Range (ATR)
- LB 0.00
- VRDN 0.78
- MACD
- LB 0.00
- VRDN 0.18
- Stochastic Oscillator
- LB 0.00
- VRDN 82.11
About LB LANDBRIDGE COMPANY LLC
LandBridge Co LLC is engaged in managing land and resources to support and promote oil and natural gas development. It generates revenue streams from the use of its surface acreage, the sale of resources from land and oil and gas royalties.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).